Literature DB >> 15224184

Ubiquitin-free routes into the proteasome.

M A Hoyt1, P Coffino.   

Abstract

The majority of proteasome substrates identified to date are marked for degradation by polyubiquitinylation. Exceptions to this principle, however, are well documented and can help us understand the process proteasomes use to recognize their substrates. Examples include ornithine decarboxylase, p21/Cip1, TCRalpha, IkappaBalpha, c-Jun, calmodulin and thymidylate synthase. Degradation of these proteins can be completely ubiquitin-independent or coexist with ubiquitin-dependent pathways. Uncoupling degradation from ubiquitin modification may reflect the evolutionary conservation of mechanisms optimized for highly specialized regulatory functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224184     DOI: 10.1007/s00018-004-4133-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  47 in total

1.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

2.  Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)--study design.

Authors:  Tone Svilaas; Iwan C C van der Horst; Felix Zijlstra
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

3.  Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.

Authors:  Roberto Diletti; Antonios Karanasos; Takashi Muramatsu; Shimpei Nakatani; Nicolas M Van Mieghem; Yoshinobu Onuma; Sjoerd T Nauta; Yuki Ishibashi; Mattie J Lenzen; Jurgen Ligthart; Carl Schultz; Evelyn Regar; Peter P de Jaegere; Patrick W Serruys; Felix Zijlstra; Robert Jan van Geuns
Journal:  Eur Heart J       Date:  2014-01-06       Impact factor: 29.983

4.  In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction.

Authors:  Lin Y Chen; Ryan J Lennon; J Aaron Grantham; Peter B Berger; Verghese Mathew; Mandeep Singh; David R Holmes; Charanjit S Rihal
Journal:  Am J Cardiol       Date:  2005-02-01       Impact factor: 2.778

5.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

Authors:  Sanjit S Jolly; Salim Yusuf; John Cairns; Kari Niemelä; Denis Xavier; Petr Widimsky; Andrzej Budaj; Matti Niemelä; Vicent Valentin; Basil S Lewis; Alvaro Avezum; Philippe Gabriel Steg; Sunil V Rao; Peggy Gao; Rizwan Afzal; Campbell D Joyner; Susan Chrolavicius; Shamir R Mehta
Journal:  Lancet       Date:  2011-04-04       Impact factor: 79.321

6.  Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.

Authors:  Tomas Jernberg; Per Johanson; Claes Held; Bodil Svennblad; Johan Lindbäck; Lars Wallentin
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

7.  Checking consistency in mixed treatment comparison meta-analysis.

Authors:  S Dias; N J Welton; D M Caldwell; A E Ades
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

8.  Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.

Authors:  Martial Hamon; Lars H Rasmussen; Steven V Manoukian; Angel Cequier; Michael A Lincoff; Hans-Jürgen Rupprecht; Bernard J Gersh; Tift Mann; Michel E Bertrand; Roxana Mehran; Gregg W Stone
Journal:  EuroIntervention       Date:  2009-05       Impact factor: 6.534

9.  Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2.

Authors:  P Widimský; T Budesínský; D Vorác; L Groch; M Zelízko; M Aschermann; M Branny; J St'ásek; P Formánek
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

10.  Thrombus aspiration complicated by systemic embolization in patients with acute myocardial infarction.

Authors:  Ming-Shyan Lin; Lung-Sheng Wu; Nai-Jen Cheng; Pi-Chi Lin; Chi-Jen Chang
Journal:  Circ J       Date:  2008-12-27       Impact factor: 2.993

View more
  45 in total

1.  Tertiary structural rearrangements upon oxidation of Methionine145 in calmodulin promotes targeted proteasomal degradation.

Authors:  Colette A Sacksteder; Jennifer E Whittier; Yijia Xiong; Jinhui Li; Nadezhda A Galeva; Michael E Jacoby; Samuel O Purvine; Todd D Williams; Martin C Rechsteiner; Diana J Bigelow; Thomas C Squier
Journal:  Biophys J       Date:  2006-06-02       Impact factor: 4.033

Review 2.  Apoptosis in infectious disease: how bacteria interfere with the apoptotic apparatus.

Authors:  Georg Häcker; Susanne Kirschnek; Silke F Fischer
Journal:  Med Microbiol Immunol       Date:  2005-08-06       Impact factor: 3.402

3.  Proteasome substrate degradation requires association plus extended peptide.

Authors:  Junko Takeuchi; Hui Chen; Philip Coffino
Journal:  EMBO J       Date:  2006-12-07       Impact factor: 11.598

4.  The cytoplasmic Hsp70 chaperone machinery subjects misfolded and endoplasmic reticulum import-incompetent proteins to degradation via the ubiquitin-proteasome system.

Authors:  Sae-Hun Park; Natalia Bolender; Frederik Eisele; Zlatka Kostova; Junko Takeuchi; Philip Coffino; Dieter H Wolf
Journal:  Mol Biol Cell       Date:  2006-10-25       Impact factor: 4.138

5.  Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer.

Authors:  Jihane Basbous; Dany Chalbos; Robert Hipskind; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2007-03-19       Impact factor: 4.272

6.  Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.

Authors:  Kwanghee Kim; James M Brush; Philip A Watson; Nicholas A Cacalano; Keisuke S Iwamoto; William H McBride
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

7.  Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions.

Authors:  Tilman Grune; Diana Botzen; Martina Engels; Peter Voss; Barbara Kaiser; Tobias Jung; Stefanie Grimm; Gennady Ermak; Kelvin J A Davies
Journal:  Arch Biochem Biophys       Date:  2010-05-15       Impact factor: 4.013

Review 8.  Regulated protein turnover: snapshots of the proteasome in action.

Authors:  Sucharita Bhattacharyya; Houqing Yu; Carsten Mim; Andreas Matouschek
Journal:  Nat Rev Mol Cell Biol       Date:  2014-02       Impact factor: 94.444

9.  Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.

Authors:  Abhishek Chandra; Luqiang Wang; Tiffany Young; Leilei Zhong; Wei-Ju Tseng; Michael A Levine; Keith Cengel; X Sherry Liu; Yejia Zhang; Robert J Pignolo; Ling Qin
Journal:  FASEB J       Date:  2017-08-31       Impact factor: 5.191

10.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.